Liposomal drug delivery system from laboratory to clinic

Journal of Postgraduate Medicine

Volumn 51, Issue 5, 2005, Pages

  Kshirsagar, N A ^a   Pandya, S K ^b   Kirodian, B G ^c   Sanath, S ^a  

^a KEM HOSPITAL   (India)

^b JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Clinical trials; Drug delivery system; Liposomal amphotericin B (L Amp LRC 1)

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; DISTEAROYLPHOSPHATIDIC ACID; FLUCONAZOLE; FUNGISOME; HYDROCORTISONE; LIPOSOME; PARACETAMOL; PENTAMIDINE; PHOSPHATIDYLCHOLINE; POTASSIUM;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APNEA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BRONCHOSPASM; CANDIDIASIS; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FEVER; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOXIA; INDIA; INDUCED HYPOTENSION; INJECTION SITE REACTION; KIDNEY GRAFT; LEISHMANIASIS; LUNG DISEASE; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; POTASSIUM BLOOD LEVEL; REVIEW; RIGOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TACHYPNEA; THORAX PAIN; THRUSH;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPOSOMES;

EID: 33645540053     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Gokhale PC, Kotwani RN, Dange SY, Kshirsagar NA, Pandya SK. Preclinical and pharmaceutical testing of liposomal Amphotericin B; Ind Jr Med Res (B) 1993;98:75-8.
2. Gokhale PC, Kshirsagar NA, Pandya SK. Development and therapeutic application of liposomal Amphotericin B; Curr Sci 1993;65:448-54.
3. Gokhale PC, Barapatre RJ, Advani SH, Kshirsagar NA, Pandya SK. Pharmacokinetics and tolerance of liposomal Amphotericin B in patients; J Antimicrob Chemother 1993;32:133-9.
4. Agarwal A, Kandpal H, Gupta HP, Singh NB, Gupta CM. Tuftsin bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice; Antimicrob Agents Chemother 1994;38:588-93.
5. Jain CP, Vyas SP. Preparation and characteristic of niosomes containing Rifampicin for lung targeting; J Microencapsul 1995;12:401-7.
6. Juliano RL, Mc Collough HN. Controlled delivery of an antitumor drug: Localised action of Liposomes encapsulated cytosine arabinoside administered via the respiratory system. J Pharmacol Exp Therap 1980;214:381-7.
7. Quenelle DC, Staas JK, Winchester GS, Barow EL, Barrow WW. Efficacy of micorencapsulation rifampin inmycobacterium infected mice. Antimicrob Agents Chemother 1999;43:1144-51.
8. Gold JW. Opportunistic fungal infections in patients with neoplastic disease. Am J Med 1984;76:485-63.
9. Sande MA, Mandell GL. Antifungal and antiviral agents; In The Pharmacological Basis of Therapeutics. Editos AG Gilman, TW Rall, AS Nies and P Taylor (New York Macmillan) 1985, p.1219-222 .
10. Clements JS, Peacok JE. Amphotericin B resisted: reassessment of toxicity; J Med Am 1990;88:22N-7N.
11. Meunier F, Prentic HG, Ringden O. Liposomal Amphotericin B (AmBisome) safety data from a phase II/III clinical trial; J Antimicrob Chemother 1991;28B:83-91.
12. New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in Liposomes. J antimicrob Chemother 1981;8:371-81.
13. ™Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE. Amphotericin B in liposomes: A novel therapy for hisptoplasmosis. Am Rev Respir 1982;125:610-1.
14. Graybill JR, Craven PC, Taylor RL, Williams DM, Magee WE. Antifungal agents used in systemic mycoses: activity and therapeutic use. J Infect Dis 1982;145:748-52.
15. Lopez- Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, et al. Treatment and prophylaxis of disseminated infection due to candida albicans in mice with liposome encapsulated Amphotericin B. J Infect Dis 1983;147:939-45.
16. Hopfer RL, Mills K, Mehta R, Lopez-Berestein G, Fainstein V, Juliano RL. Invitro antifungal activities of Amphotericin B and liposome encapsulated Amphotericin B. Antimicrob Agents Chemother 1984;25:387-9.
17. Tremblay C, Barza M, Fiore C, Szoka F. Efficacy of liposome intercalated Amphotericin B in the treatment of systemic candidiasis in mice; Antimicrob Agents Chemother 1984;26:170-3.
18. Adler-Moore JP, Chiang SM, Satorius A, Guerra D, Mc Andrews B, McManus EJ, et al. Treatment of murine candidiasis and cryptoccosis with a unilamellar Liposomal Amphotericin B formulation (AmBisome). J Antimicrob Chemother 1984;28B:63-71.
19. Abra RM, Hunt CA, Lau DT. Liposome disposition in vivo VI: Delivery to the lung. J Pharm Sci 1984;73:203-6.
20. Szoka Jr FC, Milholland D, Barza M. Effect of lipid composition and lispome size of toxicity and in vitro fungicidal activity of liposome-intercalated Amphotericin B. Antimicrob Agents Chemother 1987;31:421-9.
21. Bangham AD, Standish MM, Watkin JC. Diffusion of univalent ions across the lamellar of Swollen phospholipids. J Mol Biol 1965;13:238-52.
22. Ahmad I, Sarkar AK, Bachhawat BK. Liposomal Amphotericin B in the control of experimental aspergillosis in mice Part I Relative therapeutic efficacy of free and liposomal Amphotericin B. Indian J Biochemi Biophys 1989;26:351-6.
23. Payne NI, Cosgrove RF, Green AP, Liu L. In vivo studies of Amphotericin B Liposomes derived from proliposomes effect of formulation on toxicity and tissue dispositon of the drug in mice. J Pharm Pharmacol 1987;39:24-8.
24. Ahmad I, Sarkar AK, Bacchawat BK. Effect of cholesterol in various Liposomal compositions on the in vivo toxicity therapeutic efficacy and tissue distribution of Amphotericin B. Biotech Appl Biochem 1990;12:550-6.
25. Lopez-Berestein G, Rossenblum MG, Mehta R. Altered tissue distribution of Amphotericin B by liposomal encapuslation: Composition of normal mice to mice infected with candida albicans. Cancer Drug Delivery 1984;1:199-205.
26. Collette N, Vander Auwera P, Meunier F, Lambert C, Sculier JP, Coune A. Tissue distribution and bioactivity of Amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991;27:535-48.
27. Gondal JA, Swartz RP, Rahaman A. Therapeutic evaluation of free and liposome encapsulated Amphotericin B in the treatment of systemic candidasis in mice. Antimicrob Agents Chemother 1989;33:1544-8.
28. Lopez-Berestein G, Juliano RL. In: Liposomes from Biophysics to Therapeutics. Editor MJ Ostro Marcel (New York Dekker) 1987, p.253-76.
29. Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, et al. Liposomal Amphtoericin B for the treatment of systemic fungal infections in patients with cancer, a preliminary study. J Infect Dis 1985;151:704-10.
30. Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, et al. Treatment of systemic fungal infection with liposomal Amphotericin B. Arch Int Med 1989;149:2533-6.
31. Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984;770:230-4.
32. Sculier JR, Coune A, Meunier F, Brassinne C, Laduron C, Hollaert C, et al. Pilot study of Amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 1988;24:527-38.
33. Bodhe PV, Kotwani RN, Kirodian BG, Kshirsagar NA, Pandya SK. Open label, randomised, comparative Phase III safety and efficacy study with conventional Amphotericin B and Liposomal Amphotericin B in patients with systemic fungal infection. J Assoc Physicians India 2002;50:662-70.
34. Bodhe PV, Pathare AV, Kshirsagar NA, Pandya SK. Treatment of visceral leishmaniasis is with a 10 days course of L-ampB-LRC (Bombay) A Liposomal Amphotericin B. J Assoc Physicians India 1996;44:222.
35. Kirodian BG, Virani AR, Kshirsagar NA. Successful treatment of Cryptococcal Meningitis with Liposomal Amphotericin B (L-AMP-LRC-1) intolerant to conventional Amphotericin B. J Assoc Physicians India 2002;50:601-2.
36. Kotwani RN, Bodhe PV, Kirodian BG, Mehta KP, Ali US, Kshirsagar NA. Treatment of neonatal candidiasis with liposomal Amphotericin B (L-AMP-LRC-1): phase II study; Indian Pediatr 2003;40:545-50.
37. Kotwani RN, Gokhale PC, Bodhe PV, Kirodian BG, Kshirsagar NA. Safety and efficacy of Liposomal Amphotericin B in patients with cryptococcal meningitis. J Assoc Physicians India 2001;49:1086-90.
38. Bodhe PV, Kotwani RN, Kirodian BG, Pathare AV, Pandey AK, Thakur CP, et al. Dose ranging studies on Liposomal Amphotericin B (L-AMP- LRC-1) in the treatment of visceral leishmaniasis. Trans Roy Soc Trop Med Hyg 1999;93:314-8.
39. Gokhale PC, Kshirsagar NA, Khan MU, Pandya SK, Meisheri YV, Thakur CP, et al. Successful treatment of resistant visceral leishmaniasis with liposomal Amphotericin B. Tran Roy Soc Trop Med Hyg 1994;88:228.
40. Karande SC, Boby KF, Lahiri KR, Jain MK, Kshirsagar NA, Gokhale PC, et al. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal Amphotericin B in a child. Tropical Doct 1995;25:80-1.
41. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. In Amphotericin B: time for a new "gold standard". Clin Infect Dis 2003;37:415-25.
42. Bertrand Dupont in Overview of the lipid formulations of Amphotericin B. Jr Antimicrob Chemotherapy 2002;49:S131-6.
43. Craig J Hoesley in New Antifungal agents: Emphasis on Lipid Formulations of Amphotericin B in www.nfid.org/publications/clinical updates/fungal/june1999
44. Katz NM, Pierce PF, Anzeek RA, Vinser MS, Canter HG, Goegh ML, et al. Liposomal Amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant 1990;9:14-7.
45. Allan J Coukell, Rex N Brogden. Liposomal Amphotericin B Therapeutic use in the Management of Fungal Infections and Visceral Leishmaniasis ADIS Drug Evaluation. Drugs 1998;66:585-612.
46. Cagnoni PJ. In Liposomal Amphotericin B Versus conventional Amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Jr Antimicrob chemotherapy 2002;49:181-6.
47. Kshirsagar NA, Gokhale PC, Pandya SK. Drug treatment of systemic fungal infection: our experience with liposomal Amphotericin B. Ind Jr Hematology Blood Transfusion 1993;11:72-9.
48. Kshirsagar NA, Gokhale PC, Pandya SK. Liposomes as Drug delivery systems in leishmaniasis. J Assoc Physicians India 1995;43:46-8.
49. Kshirsagar NA, Bodhe PV, Kotwani RN. Targeted Drug Delivery in Visceral Leishmaniasis; Jr Parasitic Diseases 1997;21:21-4.
50. Kshirsagar NA. Drug Delivery Systems. Indian J Pharmacol 2000;32:S54-S61.
51. Kshirsagar NA, Kirodian BG. Liposomal Drug Delivery System from Laboratory to Patients: Our Experience. Proc Indian Natn Sci Acad 2002;B68:333-48.